AGEN Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 4.60%

Insider Buying (Last 12 Months): $345,288.00

Insider Selling (Last 12 Months): $0.00

Agenus Insider Trading History Chart

Agenus Share Price & Price History

^$4.85

▼ -0.25 (-4.90%)

As of 10/2/2024 01:00 AM ET

Days: 30 | 90 | 365

Kamala’s Dirty Election Move… Revealed

From Paradigm Press | Ad

According to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move…

Click here now and learn how to prepare.

Agenus Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/15/2024	Garo H. Armen	Insider	Buy	25,000	$13.00	$325,000.00	31,298
10/16/2023	Agenus Inc	Major Shareholder	Buy	21	$22.00	$462.00	1,088,643
10/12/2023	Agenus Inc	Major Shareholder	Buy	158	$22.00	$3,476.00	1,087,653
10/4/2023	Agenus Inc	Major Shareholder	Buy	750	$21.80	$16,350.00	1,087,494
8/28/2023	Agenus Inc	Major Shareholder	Buy	640	$29.00	$18,560.00	1,085,260
8/24/2023	Agenus Inc	Major Shareholder	Buy	8,512	$30.80	$262,169.60	1,084,620
5/10/2023	Agenus Inc	Major Shareholder	Buy	1,103	$30.20	$33,310.60	1,080,855
5/5/2023	Agenus Inc	Major Shareholder	Buy	5,010	$19.00	$95,190.00	1,079,752
5/3/2023	Agenus Inc	Major Shareholder	Buy	6,434	$21.60	$138,974.40	1,073,668
1/6/2022	Steven J. O'Day	Insider	Sell	1,933	$61.20	$118,299.60
10/19/2021	Agenus Inc	Major Shareholder	Buy	70,000	$240.00	$16,800,000.00

Revolutionary Tech Alert: How Elon Musk is Changing Lives

From InvestorPlace | Ad

"Elon Musk's Neuralink just received FDA breakthrough status for a revolutionary device designed to restore vision to those who've lost it entirely. And the first human clinical trials have opened for recruitment.

Click here to see it.

SEC Filings (Institutional Ownership Changes) for Agenus (NASDAQ:AGEN)

61.46% of Agenus stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Agenus Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
9/16/2024	Point72 DIFC Ltd	3,037	$51K	0.0%	N/A	0.014%
9/16/2024	Point72 Asia Singapore Pte. Ltd.	6,343	$0.11M	0.0%	N/A	0.030%
8/19/2024	Point72 Asset Management L.P.	260,700	$4.37M	0.0%	-99.1%	1.241%
8/15/2024	Susquehanna Fundamental Investments LLC	62,703	$1.05M	0.0%	N/A	0.299%
8/15/2024	AQR Capital Management LLC	15,425	$0.26M	0.0%	-98.7%	0.073%
8/15/2024	Point72 Asia Singapore Pte. Ltd.	6,343	$0.11M	0.0%	N/A	0.030%
8/14/2024	Squarepoint Ops LLC	36,651	$0.61M	0.0%	N/A	0.175%
8/14/2024	Oracle Investment Management Inc.	17,500	$0.29M	0.3%	-98.4%	0.083%
8/14/2024	Point72 DIFC Ltd	3,037	$51K	0.0%	N/A	0.014%
8/12/2024	Blair William & Co. IL	26,328	$0.44M	0.0%	N/A	0.125%
8/9/2024	Renaissance Technologies LLC	254,329	$4.26M	0.0%	-95.3%	1.211%
8/8/2024	Federated Hermes Inc.	114,677	$1.92M	0.0%	N/A	0.546%
8/5/2024	Ovata Capital Management Ltd	40,000	$0.67M	0.4%	N/A	0.190%
8/1/2024	Rhumbline Advisers	32,253	$0.54M	0.0%	-94.1%	0.154%
7/26/2024	Bank of New York Mellon Corp	89,599	$1.50M	0.0%	-93.5%	0.427%
7/20/2024	Hennion & Walsh Asset Management Inc.	30,319	$0.51M	0.0%	-94.6%	0.144%
7/19/2024	Values First Advisors Inc.	16,672	$0.28M	0.2%	-95.0%	0.079%
7/16/2024	Key Client Fiduciary Advisors LLC	69,754	$1.17M	0.6%	-91.9%	0.332%
5/15/2024	Oracle Investment Management Inc.	1,066,963	$0.62M	0.4%	-24.7%	5.081%
5/15/2024	Price T Rowe Associates Inc. MD	357,915	$0.21M	0.0%	+52.4%	1.704%
5/14/2024	American International Group Inc.	187,814	$0.11M	0.0%	-0.9%	0.894%
5/10/2024	Acadian Asset Management LLC	757,397	$0.44M	0.0%	+1,959.9%	3.734%
5/10/2024	Vanguard Group Inc.	34,401,122	$19.95M	0.0%	+13.7%	169.589%
5/9/2024	State Board of Administration of Florida Retirement System	57,206	$33K	0.0%	-42.8%	0.282%
5/7/2024	SG Americas Securities LLC	112,103	$65K	0.0%	-43.6%	0.553%
5/3/2024	GSA Capital Partners LLP	1,271,004	$0.74M	0.1%	-47.0%	6.267%
5/1/2024	BNP Paribas Financial Markets	188,414	$0.11M	0.0%	+81.3%	0.929%
4/29/2024	Principal Financial Group Inc.	90,825	$53K	0.0%	-10.3%	0.434%
4/17/2024	Hennion & Walsh Asset Management Inc.	558,606	$0.32M	0.0%	+2.5%	2.666%
4/16/2024	Powell Investment Advisors LLC	243,500	$0.14M	0.1%	+21.8%	1.162%
4/15/2024	Key Client Fiduciary Advisors LLC	858,969	$0.50M	0.3%	+38.0%	4.100%
4/5/2024	Los Angeles Capital Management LLC	175,272	$0.10M	0.0%	-12.7%	0.042%
3/14/2024	Ables Iannone Moore & Associates Inc.	79,000	$65K	0.0%	N/A	0.020%
2/26/2024	Virtu Financial LLC	257,437	$0.21M	0.0%	N/A	0.067%
2/20/2024	Readystate Asset Management LP	2,016,783	$1.67M	0.1%	+14.3%	0.505%
2/14/2024	Oracle Investment Management Inc.	1,416,963	$1.17M	0.7%	-33.1%	0.371%
2/14/2024	Pennant Investors LP	469,600	$0.39M	0.1%	N/A	0.123%
2/13/2024	Tower Research Capital LLC TRC	38,820	$32K	0.0%	-69.0%	0.010%
2/12/2024	Crestline Management LP	708,480	$0.59M	0.0%	+6.5%	0.186%
2/12/2024	RPO LLC	51,408	$43K	0.1%	N/A	0.013%
2/8/2024	Vanguard Personalized Indexing Management LLC	115,147	$95K	0.0%	N/A	0.030%
2/6/2024	Los Angeles Capital Management LLC	200,812	$0.17M	0.0%	+95.3%	0.053%
2/6/2024	Swiss National Bank	635,800	$0.53M	0.0%	-7.9%	0.167%
2/1/2024	Powell Investment Advisors LLC	200,000	$0.17M	0.1%	N/A	0.052%
1/30/2024	Cardinal Strategic Wealth Guidance	910,265	$0.75M	0.3%	+28.2%	0.239%
1/30/2024	PCG Wealth Advisors LLC	47,550	$39K	0.0%	+65.7%	0.012%
1/18/2024	Values First Advisors Inc.	269,829	$0.22M	0.1%	+7.8%	0.071%
1/17/2024	Assenagon Asset Management S.A.	2,306,248	$1.91M	0.0%	+3,008.8%	0.605%
1/12/2024	SG Americas Securities LLC	198,735	$0.17M	0.0%	+526.6%	0.052%
1/9/2024	Key Client Fiduciary Advisors LLC	622,469	$0.52M	0.3%	+16.3%	0.163%
1/5/2024	Exchange Traded Concepts LLC	107,019	$89K	0.0%	+34.0%	0.028%
12/18/2023	Vanguard Group Inc.	26,938,439	$30.44M	0.0%	+1.6%	7.061%
12/6/2023	Citigroup Inc.	707,213	$0.80M	0.0%	+41.0%	0.185%
11/14/2023	Oracle Investment Management Inc.	2,116,963	$2.39M	0.7%	-30.7%	0.558%
11/14/2023	Braidwell LP	6,307,030	$7.13M	0.2%	+34.3%	1.662%
11/14/2023	Caxton Associates LP	390,234	$0.44M	0.1%	+247.3%	0.103%
11/14/2023	Profund Advisors LLC	283,404	$0.32M	0.0%	+8.1%	0.075%
11/13/2023	Aigen Investment Management LP	25,307	$29K	0.0%	-54.4%	0.007%
11/13/2023	Rafferty Asset Management LLC	1,680,974	$1.90M	0.0%	+16.9%	0.443%
11/9/2023	Citigroup Inc.	707,213	$0.80M	0.0%	+41.0%	0.186%
11/8/2023	HighTower Advisors LLC	423,855	$0.48M	0.0%	-6.2%	0.112%
11/8/2023	Swiss National Bank	690,100	$0.78M	0.0%	+5.9%	0.182%
11/8/2023	First Command Advisory Services Inc.	70,618	$80K	0.0%	N/A	0.019%
11/7/2023	Barclays PLC	902,206	$1.02M	0.0%	+16.0%	0.238%
11/7/2023	Jump Financial LLC	142,133	$0.16M	0.0%	+58.9%	0.037%
11/6/2023	Assenagon Asset Management S.A.	74,184	$84K	0.0%	-67.3%	0.020%
11/6/2023	Los Angeles Capital Management LLC	102,820	$0.12M	0.0%	-73.0%	0.027%
11/2/2023	Principal Financial Group Inc.	107,291	$0.12M	0.0%	+16.7%	0.028%
10/27/2023	Hennion & Walsh Asset Management Inc.	506,942	$0.57M	0.0%	+89.5%	0.134%
10/25/2023	Lindbrook Capital LLC	52,535	$59K	0.0%	+38.8%	0.014%
10/13/2023	SG Americas Securities LLC	31,718	$36K	0.0%	N/A	0.008%
9/21/2023	Barclays PLC	777,538	$1.24M	0.0%	-20.4%	0.205%
8/15/2023	Readystate Asset Management LP	1,764,659	$2.82M	0.2%	N/A	0.465%
8/15/2023	Braidwell LP	4,697,930	$7.52M	0.2%	N/A	1.238%
8/14/2023	Oracle Investment Management Inc.	3,056,460	$4.89M	3.6%	-22.5%	0.805%
8/14/2023	Graham Capital Management L.P.	214,362	$0.34M	0.0%	N/A	0.056%
8/11/2023	Panagora Asset Management Inc.	1,144,807	$1.83M	0.0%	-24.2%	0.302%
8/11/2023	E Fund Management Co. Ltd.	77,312	$0.12M	0.0%	-37.6%	0.020%
8/11/2023	ExodusPoint Capital Management LP	1,714,780	$2.74M	0.0%	N/A	0.492%
8/10/2023	Profund Advisors LLC	262,142	$0.42M	0.0%	-34.9%	0.075%
8/9/2023	BNP Paribas Arbitrage SNC	360,232	$0.58M	0.0%	-61.8%	0.103%
8/7/2023	Principal Financial Group Inc.	91,921	$0.15M	0.0%	-28.6%	0.026%
8/7/2023	Mirabella Financial Services LLP	28,542	$46K	0.0%	N/A	0.008%
8/4/2023	American International Group Inc.	165,110	$0.26M	0.0%	+12.3%	0.047%
8/3/2023	Los Angeles Capital Management LLC	381,310	$0.61M	0.0%	+5.8%	0.109%
8/3/2023	Dearborn Partners LLC	23,358	$37K	0.0%	+50.1%	0.007%
8/3/2023	Barclays PLC	777,538	$1.24M	0.0%	-20.4%	0.223%
8/3/2023	Mackenzie Financial Corp	38,630	$59K	0.0%	+68.8%	0.011%
8/3/2023	Bank of New York Mellon Corp	1,247,036	$2M	0.0%	+27.3%	0.357%
7/31/2023	Strs Ohio	88,800	$0.14M	0.0%	-63.6%	0.025%
7/31/2023	Lindbrook Capital LLC	37,861	$61K	0.0%	+1,934.4%	0.011%
7/25/2023	Assenagon Asset Management S.A.	227,065	$0.36M	0.0%	+31.3%	0.065%
7/20/2023	Exchange Traded Concepts LLC	72,522	$0.12M	0.0%	N/A	0.021%
7/18/2023	Diversified Trust Co	58,252	$93K	0.0%	+147.4%	0.017%
7/13/2023	Key Client Fiduciary Advisors LLC	541,586	$0.87M	0.5%	+1.9%	0.155%
5/12/2023	Panagora Asset Management Inc.	1,510,860	$2.30M	0.0%	+33.7%	0.454%
5/12/2023	Profund Advisors LLC	402,454	$0.61M	0.0%	N/A	0.121%
5/11/2023	Citigroup Inc.	1,879,754	$2.86M	0.0%	+144.6%	0.565%
5/11/2023	E Fund Management Co. Ltd.	123,851	$0.19M	0.0%	+35.0%	0.037%
5/8/2023	Zurcher Kantonalbank Zurich Cantonalbank	48,970	$74K	0.0%	+17.9%	0.015%

Data available starting January 2016

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Today's Range

Now: $4.85

$4.84

$5.22

50 Day Range

MA: $5.44

$4.58

$6.56

52 Week Range

Now: $4.85

$4.41

$23.20

Volume

509,819 shs

Average Volume

684,394 shs

Market Capitalization

$101.85 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.36

Who are the company insiders with the largest holdings of Agenus?: Agenus' top insider shareholders include:
Agenus Inc (Major Shareholder)
Garo H Armen (Insider)
Learn More about top insider investors at Agenus.